CTAD 2025 1 - 4 December 2025

Semaglutide impacts proteomic signatures related to dementia risk in the SELECT cardiovascular outcomes trial

Authors :

Martí Jiménez-Mausbach1; Jan Christian Refsgaard1; Gabriel Martino1; Teresa Leon Colombo1; Betty Tijms2; Clare Paterson3

Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Download poster (.pdf)
Keywords
Neurology
Congress poster
GLP-1 RA
Semaglutide (oral)
PHASE 2 (RCT)